About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
  • Smad2/3 Signaling

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    The TGF-β superfamily comprises multifunctional signaling proteins and key regulators of homeostasis and repair throughout the body.1 Dysfunction of TGF-β superfamily members has been implicated in cancer and other pathological conditions. Ligands in this superfamily mediate their diverse effects by inducing distinct combinations of type I and II receptors and their downstream effectors—Smad proteins.1

    Preclinical studies have shown that Smad2/3 signaling, mediated by members of the TGF-β superfamily, may have effects on erythroid precursors2-4 and is involved in regulating late-stage erythropoiesis.5-7 Defective late-stage erythropoiesis results in impaired red blood cell maturation, leading to anemia and contributing to iron overload.8,9 However, the specific roles of Smad2/3 signaling in red blood cell production have not been fully elucidated. In a mouse model of β-thalassemia, inhibition of abnormally elevated Smad2/3 signaling improved hematology parameters associated with ineffective erythropoiesis.10

    View Related Molecules

    References

    1. Piek E, et al. FASEB J. 1999;13:2105-2124. PMID: 10593858
    2. Blank U, Karlsson S. Leukemia. 2011;25:1379-1388. PMID: 21566654
    3. Shiozaki M, et al. Proc Natl Acad Sci U S A. 1992;89:1553-1556. PMID: 1542647
    4. Shav-Tal Y, Zipori D. Stem Cells. 2002;20:493-500. PMID: 12456957
    5. Carrancio S, et al. Br J Haematol. 2014;165:870-882. PMID: 24635723
    6. Suragani RN, et al. Nat Med. 2014;20:408-414. PMID: 24658078
    7. Zermati Y, et al. Exp Hematol. 2000;28:885-894. PMID: 10989189
    8. Attie KM, et al. Am J Hematol. 2014;89:766-770. PMID: 24715706
    9. Suragani RN, et al. Nat Med. 2014;20:408-414. PMID: 24658078
    10. Suragani RN, et al. Blood. 2014;123:3864-3872. PMID: 24795345